Concomitant moderate or greater left-sided valvular heart disease in patients undergoing T-TEER independently predicted mortality (HR 1.54; 95% CI 1.21-1.96; p<0.001).
Observational (n=1,647)
Yes
Does concomitant left-sided valvular heart disease worsen survival and heart failure hospitalizations in patients undergoing T-TEER for tricuspid regurgitation?
Concomitant moderate or greater left-sided valvular heart disease is common and independently predicts worse survival and higher heart failure hospitalization rates in patients undergoing T-TEER, though symptomatic and TR reduction benefits remain.
Effect estimate: HR 1.54 (95% CI 1.21-1.96)
p-value: p=<0.001
Background And Aims The impact of coexisting left-sided valvular heart disease (VHD) on clinical outcomes following tricuspid valve edge-to-edge repair (T-TEER) for tricuspid regurgitation (TR) remains unclear, particularly under real-world conditions.Objectives To evaluate the prevalence and prognostic impact of concomitant left-sided VHD in patients undergoing T-TEER.Methods This study included all patients undergoing T-TEER from EuroTR (European Registry of Transcatheter Repair for Tricuspid Regurgitation; NCT06307262) with complete echocardiographic data on left sided valve disease. Study endpoints included survival and heart failure hospitalizations (HFH) at 2 years, NYHA functional class and TR reduction.Results Among a total of 1,647 eligible patients, 95.8%, 35.6% and 3.8% had ≥ mild, moderate and severe concomitant VHD, respectively. Moderate or higher VHD was associated with a significantly reduced 2-year survival (p<0.001) and reduced 2-year HFH-free survival (p=0.005). Multivariate regression analysis confirmed ≥ moderate VHD to be an independent predictor of mortality (Hazard ratio 1.54, 95% CI 1.21-1.96, p<0.001). Despite worse TR and NYHA functional class at baseline in patients with ≥ moderate VHD, T-TEER was associated with a significant TR reduction (p<0.001) and symptomatic improvement (p<0.001).Conclusions Concomitant left-sided VHD is common among patients undergoing T-TEER and is independently associated with worse survival and higher rates of HFH. Nevertheless, T-TEER provides meaningful symptomatic benefit and durable TR reduction in patients with and without VHD burden.
Gmeiner et al. (2026) conducted an observational in Tricuspid regurgitation with concomitant left-sided valvular heart disease (n=1,647). Tricuspid valve transcatheter edge-to-edge repair (T-TEER) was evaluated on Mortality (HR 1.54, 95% CI 1.21-1.96, p=<0.001). Concomitant moderate or greater left-sided valvular heart disease in patients undergoing T-TEER independently predicted mortality (HR 1.54; 95% CI 1.21-1.96; p<0.001).